Tryp Therapeutics Inc.

Equities

TRYP

CA89854F1062

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 02:08:47 2024-04-29 pm EDT			5-day change	1st Jan Change
0.06 ^CAD	0.00%		+9.09%	+50.00%

Mar. 08	Tryp Therapeutics Inc. announced that it has received AUD 3.39 million in funding	CI
Feb. 05	Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	CI

Tryp Therapeutics Inc. Reports Earnings Results for the Full Year Ended August 31, 2023

December 29, 2023 at 06:35 pm EST

Tryp Therapeutics Inc. reported earnings results for the full year ended August 31, 2023. For the full year, the company reported net loss was CAD 5.27 million compared to CAD 7.49 million a year ago.

Latest news about Tryp Therapeutics Inc.

Tryp Therapeutics Inc. announced that it has received AUD 3.39 million in funding	Mar. 07	CI
Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	Feb. 05	CI
Tryp Therapeutics and Exopharm Limited Secures Pivotal $0.02 Waiver From ASX	Jan. 26	MT
Tryp Therapeutics Announces "Significant Milestone" in Clinical Trial Program for (IV-infused Psilocin	Jan. 08	MT
Tryp Therapeutics Inc. Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at the University of Michigan	Jan. 04	CI
Tryp Therapeutics Says First Patient Dosed in Phase 2a Clinical Trial for Treatment of Fibromyalgia at University of Michigan	Jan. 04	MT
Tryp Therapeutics Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	Dec. 29	CI
Tryp Therapeutics Inc. acquired Tryptamine Therapeutics Australia PTY LTD.	Dec. 28	CI
3,043,860 Common Shares of Tryp Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 18-DEC-2023.	Dec. 17	CI
Tryp Therapeutics Inc. entered into a definitive agreement to acquire Exopharm Limited for CAD 7.2 million in a reverse merger transaction.	Dec. 10	CI
Tryp Therapeutics Inc. announced that it has received AUD 3.215 million in funding	Nov. 19	CI
Tryp Therapeutics Inc. announced that it expects to receive AUD 3 million in funding	Nov. 01	CI
Tryp Therapeutics Inc. announced that it has received AUD 0.175 million in funding	23-10-10	CI
Tryp Therapeutics Inc. announced that it expects to receive AUD 0.175 million in funding	23-10-03	CI
Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023	23-08-03	CI
Tryp Therapeutics Inc. Announces the Passing of David Tousley, Director	23-08-02	CI
Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2A Clinical Trial in Patients with IBS At Massachusetts General Hospital	23-08-01	CI
Tryp Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-31	CI
Tryp Therapeutics Receives FDA Confirmation to Proceed With Phase 2A Clinical Trial in Patients With IBS	23-07-13	MT
3,043,860 Common Shares of Tryp Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 20-JUN-2023.	23-06-19	CI
Tryp Therapeutics Submits Investigational New Drug Application to US FDA for Phase 2a Clinical Trial in Patients With IBS	23-05-24	MT
Tryp Therapeutics Brief: Submitting Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital	23-05-24	MT
Tryp Therapeutics Submits Investigational New Drug Application to US FDA for Planned Phase 2a Clinical Trial in Patients with IBS at Massachusetts General Hospital	23-05-24	CI
Tryp Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-28	CI
Tryp Therapeutics Inc. announced that it has received AUD 2.4 million in funding	23-04-26	CI

Chart Tryp Therapeutics Inc.

Duration

Period

More charts

Company Profile

Tryp Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The Companyâs lead development program, Psilocybin-For-Neuropsychiatric Disorders (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The primary indications for its PFN are in the areas of chronic pain, including fibromyalgia, phantom limb pain and complex regional pain syndrome, and eating disorders, including binge eating and hypothalamic obesity. The Company's product pipeline includes TRP-8802 and TRP-8803. TRP-8803 uses a formulation and route of administration to improve the patient experience.

Sector

Biotechnology & Medical Research

Calendar

2024-07-24 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.06

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TRYP THERAPEUTICS INC.	+50.00%	4.23M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research